SinoMab BioScience Limited (HKG:3681)
Hong Kong · Delayed Price · Currency is HKD 1.000
-0.015 (-1.48%)
Nov 3, 2026, 4:08 PM HKT
SinoMab BioScience Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
73
Market Cap
1.39B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 2.03M | 661.00K | 48.42% |
| Dec 31, 2023 | 1.37M | -2.67M | -66.15% |
| Dec 31, 2022 | 4.03M | -22.63M | -84.87% |
| Dec 31, 2021 | 26.66M | 13.90M | 108.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.50B |
| AIM Vaccine | 1.16B |
| Mabpharm | 888.77M |
| Guangzhou Innogen Pharmaceutical Group | 176.96M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 170.32M |
| Beijing Biostar Pharmaceuticals | 63.74M |
| Zhaoke Ophthalmology | 40.41M |
| Cloudbreak Pharma | 2.11M |